Completed OBSERVATIONAL NCT00690859

Predictors of Recurrence in Bipolar Disorder in Spain (PREBIS)

Evaluation of Predictor Factors of Recurrence in Bipolar Disorder in Spain

Sponsor: AstraZeneca

Updated 8 times since 2017 Last updated: Jan 21, 2020 Started: Jun 30, 2007 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Bipolar Disorder, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 8 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Andújar, Spain , Arganda, Spain , Arucas, Spain , Banaderos, Spain , Barakaldo, Spain , Barcelona, Spain , Burgos, Spain , Calahorra, Spain , Conxo, Spain , Coria, Spain and 39 more locations